Down-regulation of the human ether-a-go-go-related gene in rat cardiac hypertrophy

American Journal of the Medical Sciences

Volumn 341, Issue 2, 2011, Pages 119-125

  Hu, Chuangjia ^a   Yan, Chunying ^a   Lin, Jijin ^b   Liu, Shukai ^a,b   Li, Yanyan ^a,b  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Abdominal aortic coarctation; Cardiac hypertrophy; Human ether a go gorelated (HERG) gene; QT prolongation

Indexed keywords

MESSENGER RNA; POTASSIUM CHANNEL HERG;

ABDOMINAL AORTA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA COARCTATION; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ELECTROCARDIOGRAM; FEMALE; HEART HEMODYNAMICS; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PROTEIN EXPRESSION; QT PROLONGATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; WESTERN BLOTTING;

EID: 79951513316     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181f73f81     Document Type: Article

References (34)

1. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003;65:45-79. (Pubitemid 38249147)
2. Kang YJ. Cardiac hypertrophy: a risk factor for QT-prolongation and cardiac sudden death. Toxicol Pathol 2006;34:58-66.
3. Kaplinsky E. Significance of left ventricular hypertrophy in cardiovas-cular morbidity and mortality. Cardiovasc Drugs Ther 1994;8(suppl 3):549-56. (Pubitemid 24347240)
4. Schmieder RE, Messerli FH. [Ventricular arrhythmia and sudden cardiac death: the significance of left ventricular hypertrophy as risk factor]. Schweiz MedWochenschr 1993;123:99-107. (Pubitemid 23041805)
5. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003; 58:32-45. (Pubitemid 36351620)
6. Cheng JH, Kodama I. Two components of delayed rectifier K + current in heart: molecular basis, functional diversity, and contribution to repolarization. Acta Pharmacol Sin 2004;25:137-45. (Pubitemid 38186160)
7. Charpentier F, Merot J, Loussouarn G, et al. Delayed rectifier K(+) currents and cardiac repolarization. J Mol Cell Cardiol 2010;48:37-44.
8. Ficker E, Kuryshev YA, Dennis AT, et al. Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 2004; 66:33-44. (Pubitemid 38822085)
9. Wang L, Wible BA, Wan X, et al. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking. J Pharmacol Exp Ther 2007;320:525-34. (Pubitemid 46147930)
10. Everett AD, Tufro-McReddie A, Fisher A, et al. Angiotensin recep-tor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression. Hypertension 1994;23:587-92.
11. Mitchell GF, Jeron A, Koren G. Measurement ofheart rate and Q-T interval in the conscious mouse. Am J Physiol 1998;274:H747-51.
12. Ohkusa T, Hisamatsu Y, Yano M, et al. Altered cardiac mechanism and sarcoplasmic reticulum function in pressure overload-induced car-diac hypertrophy in rats. J Mol Cell Cardiol 1997;29:45-54. (Pubitemid 27129129)
13. Livak KJ, Schmittgen TD. Analysis ofrelative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-8. (Pubitemid 34164012)
14. Antzelevitch C. Ionic, molecular, and cellular bases of QT-interval prolongation andtorsade de pointes. Europace 2007;9(suppl 4):iv4-15.
15. Luo X, Xiao J, Lin H, et al. Genomic structure, transcriptional control, and tissue distribution of HERG1 and KCNQ1 genes. Am J Physiol Heart Circ Physiol 2008;294:H1371-80. (Pubitemid 351468736)
16. Hoorntje T, Alders M, van Tintelen P, et al. Homozygous premature truncation of the HERG protein: the human HERG knockout. Circula-tion 1999;100:1264-7. (Pubitemid 29440116)
17. Johnson WH Jr, Yang P, Yang T, et al. Clinical, genetic, and biophysical characterization of a homozygous HERG mutation causing severe neonatal long QT syndrome. Pediatr Res 2003; 53:744-8. (Pubitemid 36504715)
18. Anderson CL, Delisle BP, Anson BD, et al. Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism. Circulation 2006;113:365-73. (Pubitemid 43803197)
19. Morissette P, Hreiche R, Mallet L, et al. Olanzapine prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J Psychopharmacol 2007;21:735-41. (Pubitemid 47437909)
20. Witchel HJ, Hancox JC. Familial and acquired long QT syndrome and the cardiac rapid delayed rectifier potassium current. Clin Exp Pharma-col Physiol 2000;27:753-66.
21. Ferrer-Villada T, Navarro-Polanco RA, Rodriguez-Menchaca AA, et al. Inhibition ofcardiac HERG potassium channels by antidepressant maprotiline. Eur J Pharmacol 2006;531:1-8. (Pubitemid 43202207)
22. Kang J, Chen XL, Wang L, et al. Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG. J Pharmacol Exp Ther 2001;299:290-6. (Pubitemid 32905146)
23. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006;440:463-9.
24. Scherer D, von Lowenstern K, Zitron E, et al. Inhibition of cardiac hERG potassium channels by tetracyclic antidepressant mianserin. Naunyn Schmiedebergs Arch Pharmacol 2008;378:73-83.
25. Sun H, Liu X, Xiong Q, et al. Chronic inhibition ofcardiac Kir2.1 and HERG potassium channels by celastrol with dual effects on both ion conductivity and protein trafficking. J Biol Chem 2006;281:5877-4.
26. Xiao J, Luo X, Lin H, et al. MicroRNA miR-133 represses HERG K + channel expression contributing to QT prolongation in diabetic hearts. J Biol Chem 2007;282:12363-7. (Pubitemid 47100573)
27. Rame JE, Dries DL. Heart failure and cardiac hypertrophy. Curr Treat Options Cardiovasc Med2007;9:289-301. (Pubitemid 47181095)
28. Polizio AH, Gorzalczany S, Taira C, et al. Aortic coarctation induces oxidative stress in rat tissues. Life Sci 2006;79:596-600.
29. Nabauer M, Kaab S. Potassium channel down-regulation in heart failure. Cardiovasc Res 1998;37:324-34. (Pubitemid 28165994)
30. Tomaselli GF, Marban E. Electrophysiological remodeling in hyper-trophy and heart failure. Cardiovasc Res 1999;42:270-83. (Pubitemid 29243156)
31. Wang Y, Cheng J, Chen G, et al. Remodeling ofoutwardK+ currents in pressure-overload heart failure. J Cardiovasc Electrophysiol 2007; 18:869-75. (Pubitemid 47093072)
32. Sakatani T, Shirayama T, Yamamoto T, et al. Cardiac hypertrophy diminished the effects of isoproterenol on delayed rectifier potassium current in rat heart. J Physiol Sci 2006;56:173-81. (Pubitemid 46955930)
33. Antzelevitch C, Shimizu W, Yan GX, et al. The M cell: its contri-bution to the ECG and to normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol 1999;10:1124-52. (Pubitemid 29383677)
34. Ramakers C, Vos MA, Doevendans PA, et al. Coordinated down-regulation ofKCNQ1 and KCNE1 expression contributes to reduc-tion ofI(Ks) in canine hypertrophied hearts. Cardiovasc Res 2003; 57:486-96. (Pubitemid 36149752)